<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844646</url>
  </required_header>
  <id_info>
    <org_study_id>49402</org_study_id>
    <secondary_id>P30DK116074</secondary_id>
    <nct_id>NCT03844646</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes</brief_title>
  <official_title>Real-Time Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether intermittent use of continuous
      glucose monitor will facilitate weight loss in individuals who are overweight/obese with
      prediabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous glucose monitoring (CGM) has revolutionized the treatment of patients on intensive
      insulin therapy and its utility can also be harnessed to help individuals with prediabetes
      make healthful lifestyle changes. Successful weight loss requires adherence to lower
      calories, regular exercise, and self-monitoring. This proposal will test the hypothesis that
      intermittent CGM will facilitate all of these components for successful weight loss by
      functioning as a continuous self-monitor and guiding healthful food choices and physical
      activity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of weight lost (kg)</measure>
    <time_frame>Baseline to end of study (3 months)</time_frame>
    <description>Weight lost during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in moderate physical activity</measure>
    <time_frame>Baseline to end of study (3 months)</time_frame>
    <description>Change in number of minutes of moderate physical activity (brisk walking)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Weight Loss</condition>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>CGM plus dietitian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent use of a continuous glucose monitor (CGM) plus dietitian support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietitian only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dietitian support only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGM</intervention_name>
    <description>Intermittent use of a continuous glucose monitor (CGM)</description>
    <arm_group_label>CGM plus dietitian</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietitian</intervention_name>
    <description>Monthly meetings with a dietitian</description>
    <arm_group_label>CGM plus dietitian</arm_group_label>
    <arm_group_label>Dietitian only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight/obese (BMI 25-40 kg/m2)

          -  Prediabetes (fasting glucose 100-125 mg/dL and/or HbA1c 5.7-6.4%)

        Exclusion Criteria:

          -  On glucose-lowering medications (e.g., metformin)

          -  On weight-loss medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Professor</last_name>
    <phone>(650) 723-8284</phone>
    <email>sunhkim@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Associate Professor</last_name>
      <phone>650-723-8284</phone>
      <email>sunhkim@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sun H Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

